![]() In those situations, the program may change its terms. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. The program is intended to help patients afford DUPIXENT. Any savings provided by the program may vary depending on patients' out-of-pocket costs. DUPIXENT MyWay ® reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. This program is not valid where prohibited by law, taxed or restricted. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. Program has an annual maximum of $13,000. The patient or caregiver must be aged 18 years or older to be eligible.Įligible patients covered by commercial health insurance may pay as little as $0 a copay per fill of DUPIXENT (maximum of $13,000 per patient per calendar year).ĪApproval is not guaranteed. Patients may be eligible for the DUPIXENT MyWay ® Copay Card if they have commercial insurance, have a DUPIXENT prescription for an FDA-approved condition, and are a resident of the 50 United States, District of Columbia, Puerto Rico, Guam or the USVI. 8ĬRSwNP, chronic rhinosinusitis with nasal polyposis INCS, intranasal corticosteroid SCS, systemic corticosteroid NSAID-ERD, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. 1Ī All patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray. The total population of patients in SINUS-24 and SINUS-52 was unrestricted by minimum baseline blood eosinophil count. Rescue with systemic corticosteroids or surgery was allowed at investigators’ discretion. Patients with chronic rhinosinusitis without nasal polyposis were not included in these trials. 60% of patients had history of asthma, and 27% had NSAID-ERD. ~79% of patients enrolled in both trials had atopic diseases. Prior surgery patients had a mean of 2.0 prior surgeries, and SCS use patients had 1.6 SCS courses in the previous 2 years. In both SINUS-24 and SINUS-52, 73% to 90% of subjects had opacification of all sinuses. Adults (≥18 years) on background INCS a with CRSwNP were included despite prior sino-nasal surgery or prior treatment with, or who were ineligible to receive or were intolerant to, systemic corticosteroids in the past 2 years were enrolled in the clinical trials. See what polyp reduction looks like with DUPIXENTĭUPIXENT was studied in the largest clinical trial program to date for CRSwNP: 724 total participants SINUS-24: 276, Trial 2: 448, Combined: 724. INCS, intranasal corticosteroid LSM, least squares mean Q2W, once every 2 weeks. ![]() Nasal endoscopy: reduced score indicates improvement. Nasal polyp score (NPS) is the sum of right and left nostril scores (range 0 to 8) as evaluated by Worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference vs placebo: -2.40 [95% CI: -2.77, -2.24 improvement in NPS at Week 52 with DUPIXENT 300 mg Q2W + INCS (n=150) (baseline score 6.07) vs 0.15.Score 6.18) vs 0.10 worsening with placebo + INCS (n=153) (baseline score 5.96) (LSM difference vs placebo: -1.71 improvement in NPS at Week 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (baseline.In the same study, patients saw a significant reduction in the size of nasal polyps, as measured by NPS: Learn more about how quickly DUPIXENT can improve sense of smellĭUPIXENT reduced polyp burden as early as Week 4 (LSM difference vs placebo: -1.15 ) in University of Pennsylvania Smell Identification Test (UPSIT) score (range 0 to 40): higher score indicates improvement. (Post hoc analysis result is descriptive) Improvement in sense of smell was investigated in 2 measures: UPSIT score and daily loss of smell score.Ī Analysis of change at Week 52 was not multiplicity controlled result is descriptive.ī Patient reported loss of smell as compared to placebo throughout the study period (LSM difference vs placebo at Day 3: -0.07 ). Smell improvement was observed as early as Day 3. That improvement was sustained through Week 52 in the same study, increasing to 71% with DUPIXENT (baseline score 13.46) vs 6% worsening with placebo (baseline score 13.78) (LSM difference: 10.30 ) (other secondary endpoint). ![]() ![]() In SINUS-52, 67% of total improvement in sense of smell was seen after the first dose of DUPIXENT, as measured at Week 2 (LSM difference vs placebo: 5.36 ). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |